- Home
- SWTX
as 11-15-2024 4:00pm EST
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 2.2B | IPO Year: | 2019 |
| Target Price: | $65.40 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.19 - $53.92 | Next Earning Date: | 11-12-2024 |
| Revenue: | $135,487,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 3498.68% | Revenue Growth (next year): | 98.08% |
Stock Insider Trading Activity of SpringWorks Therapeutics Inc. (SWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Edris Badreddin | SWTX | Chief Operating Officer | Sep 3 '24 | Sell | $41.10 | 20,000 | $812,954.35 | 237,300 | |
| Islam Saqib | SWTX | Chief Executive Officer | Sep 3 '24 | Sell | $41.09 | 49,000 | $1,988,033.06 | 1,079,968 |
Latest SpringWorks Therapeutics Inc. News
SWTX Breaking Stock News: Dive into SWTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report
GuruFocus.com
4 days ago
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
GlobeNewswire
5 days ago
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
TipRanks
5 days ago
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study
GlobeNewswire
5 days ago
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GuruFocus.com
6 days ago
Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result
GlobeNewswire
6 days ago
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
GlobeNewswire
6 days ago
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
Compare SWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SWTX SpringWorks Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.